Can I Take Vitamin B12 with Praluent (Alirocumab)?

The Short Answer: No Interaction Exists Between Vitamin B12 and Alirocumab

Taking vitamin B12 alongside Praluent (alirocumab) is safe. Alirocumab is a fully human monoclonal IgG1 antibody that targets PCSK9. It is not processed by cytochrome P450 enzymes, glucuronyl transferases, or any of the hepatic pathways that govern small-molecule drug interactions. Vitamin B12 is a water-soluble cofactor absorbed via intrinsic-factor-mediated endocytosis in the terminal ileum, and it shares none of alirocumab's biological targets.

Why Pharmacokinetic Interactions Cannot Occur

Small-molecule drugs compete for the same hepatic enzymes, transporter proteins, and renal secretion channels. Monoclonal antibodies such as alirocumab bypass this entire system. They are catabolized through nonspecific proteolysis into amino acids, the same pathway used to break down any dietary protein. The FDA prescribing information for Praluent states explicitly: "No dedicated drug-drug interaction studies have been conducted with Praluent," because the monoclonal antibody structure removes the mechanistic basis for classic pharmacokinetic interactions. [1]

Why Pharmacodynamic Interactions Cannot Occur

A pharmacodynamic interaction requires two agents to act on the same receptor, the same downstream signaling cascade, or competing physiological outcomes. Alirocumab binds PCSK9 in the extracellular space, preventing PCSK9 from tagging hepatic LDL receptors for degradation. B12 acts intracellularly as a methyl-group donor and enzymatic cofactor. These pathways do not converge. There is no evidence from ODYSSEY LONG TERM, ODYSSEY OUTCOMES, or any published PCSK9-inhibitor trial that B12 status modifies cardiovascular or lipid-lowering outcomes for this drug class.

Understanding Praluent: Mechanism and Clinical Context

Alirocumab received FDA approval in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

How Alirocumab Lowers LDL-C

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted by hepatocytes. After it binds to LDL receptors on the hepatocyte surface, the entire PCSK9-LDL receptor complex is internalized and degraded. Fewer surface LDL receptors means less LDL clearance from plasma.

Alirocumab binds PCSK9 with high affinity (K_D approximately 0.3 nM), blocking the PCSK9-LDL-receptor interaction. The rescued LDL receptors recycle to the cell surface, raising hepatic LDL uptake and dropping plasma LDL-C by 46 to 61% from baseline. [2]

Evidence Base

ODYSSEY LONG TERM (N=2,341) randomized patients on maximally tolerated statins to alirocumab 150 mg subcutaneously every two weeks versus placebo. At 24 weeks, LDL-C fell 61.9% in the alirocumab group versus 0.8% in the placebo group (P<0.001). [2]

ODYSSEY OUTCOMES (N=18,924) enrolled patients with acute coronary syndrome and showed alirocumab reduced the composite of coronary heart disease death, non-fatal MI, ischemic stroke, and unstable angina requiring hospitalization by 15% compared with placebo (hazard ratio 0.85, 95% CI 0.78-0.93, P<0.001). [3]

Who Typically Takes Praluent

The typical alirocumab patient is 55 to 70 years old, on high-intensity statin therapy, and often co-prescribed metformin for type 2 diabetes. This demographic detail is clinically significant when vitamin B12 comes into the picture. Not because of alirocumab, but because of metformin.

Why B12 Actually Matters in This Patient Population

Metformin Depletes Vitamin B12

Metformin, the first-line oral agent for type 2 diabetes, reduces B12 absorption through a calcium-dependent mechanism involving competitive displacement of the intrinsic factor-B12 complex at ileal cubilin receptors. The effect is dose-dependent and progressive. A 2006 randomized controlled trial by de Jager et al. (N=390, 4-year follow-up) showed B12 levels fell by a mean of 19% in the metformin group versus a rise of 5% in the placebo group. [4]

Clinical deficiency (serum B12 <200 pg/mL) develops in approximately 7 to 10% of long-term metformin users, while sub-optimal levels (<300 pg/mL) affect closer to 20 to 30% of this population. [5]

B12 Deficiency and Peripheral Neuropathy

Low B12 impairs myelin synthesis by disrupting the methionine synthase reaction, which converts homocysteine to methionine. The result is progressive demyelination of peripheral sensory nerves. This condition is clinically indistinguishable from diabetic peripheral neuropathy and is easily missed unless B12 is specifically measured. [6]

A cohort study published in Diabetes Care (N=1,146) found that metformin users had a 1.62-fold higher odds of B12 deficiency compared with non-users (OR 1.62, 95% CI 1.13-2.33) and that those with deficiency had significantly higher rates of peripheral neuropathy symptoms. [7]

The Practical Implication for Praluent Patients

Many patients prescribed alirocumab have established ASCVD plus type 2 diabetes. This means metformin co-prescribing is common in this group. The B12 question is not theoretical for them. Annual B12 monitoring is appropriate, and supplementation makes sense when levels are suboptimal.

The American Diabetes Association Standards of Medical Care in Diabetes states: "Periodic measurement of vitamin B12 levels should be considered in patients on metformin therapy, especially in those with peripheral neuropathy or anemia." [8]

Vitamin B12: What It Does and Who Needs to Supplement

Physiological Roles

Vitamin B12 (cobalamin) serves two enzymatic functions in humans. First, it acts as a cofactor for methylmalonyl-CoA mutase, converting methylmalonyl-CoA to succinyl-CoA in mitochondria. Second, it supports cytosolic methionine synthase, which regenerates methionine from homocysteine and simultaneously recycles folate to its active tetrahydrofolate form.

Without adequate B12, both pathways stall. Methylmalonic acid accumulates (a sensitive early marker of deficiency), homocysteine rises, and DNA synthesis in rapidly dividing cells falters.

Forms of B12 and Absorption

Four cobalamin forms exist: cyanocobalamin, methylcobalamin, adenosylcobalamin, and hydroxocobalamin. Cyanocobalamin is the most studied and least expensive oral form; it requires conversion to active cofactor forms in tissues. Methylcobalamin is already in its active methyl-donor form and may be preferred in patients with MTHFR polymorphisms, though head-to-head clinical outcomes data comparing forms in non-deficient adults are limited.

Oral absorption at physiological doses (1-2 mcg) depends entirely on intrinsic factor. At pharmacological doses (500-1,000 mcg), roughly 1% is absorbed by passive diffusion, bypassing intrinsic factor entirely. This is why high-dose oral B12 corrects deficiency even in pernicious anemia or metformin-mediated absorption impairment.

Reference Ranges and Deficiency Thresholds

Standard laboratory reference ranges list serum B12 cutoffs of 200-900 pg/mL, with deficiency defined at <200 pg/mL. Many clinicians consider 200-300 pg/mL a "gray zone" requiring confirmation with methylmalonic acid (MMA) and homocysteine levels. Elevated MMA (>0.28 micromol/L) provides functional evidence of cellular B12 deficiency even when serum B12 is within the low-normal range.

Practical Guidance: Taking B12 Alongside Praluent

The following four-step framework applies to any patient on alirocumab who is considering or already taking vitamin B12 supplementation.

Step 1. Confirm Whether B12 Is Actually Needed

Routine B12 supplementation without an identified reason adds cost but carries minimal risk given its safety profile. Check for these indications before recommending supplementation:

• Metformin use for longer than 12 months
• Vegan or strict vegetarian diet (animal products are the only dietary B12 source)
• Age older than 65 (gastric atrophy reduces intrinsic factor production)
• Prior gastric bypass or ileal resection
• Proton pump inhibitor use for longer than 2 years
• Serum B12 below 300 pg/mL on a recent metabolic panel

Step 2. Choose the Right Form and Dose

For patients with no malabsorption issue who simply want nutritional insurance, 500-1,000 mcg of oral cyanocobalamin daily is both safe and sufficient. For documented deficiency in a metformin user, 1,000 mcg oral cyanocobalamin daily corrects most cases within 8-12 weeks; a 2009 trial by Bauman et al. Confirmed oral B12 at this dose is as effective as intramuscular injection for the majority of patients with dietary or drug-related deficiency (not autoimmune pernicious anemia). [9]

Intramuscular hydroxocobalamin 1 mg monthly remains the standard for confirmed pernicious anemia or severe symptomatic deficiency where rapid repletion is required.

Step 3. No Timing Restriction With Praluent

Alirocumab is injected subcutaneously once every two weeks (75 mg or 150 mg). It is not absorbed via the GI tract and has no absorption window that B12 could interfere with. Take B12 at whatever time of day is most convenient. Morning dosing with a meal tends to improve adherence in practice.

Step 4. Monitor After Repletion

Recheck serum B12 and, if initially elevated, MMA levels at 8-12 weeks after starting supplementation. Once levels stabilize above 400 pg/mL, annual rechecks are sufficient for most patients. For those on ongoing metformin, annual monitoring aligns with ADA guideline recommendations regardless of current B12 status. [8]

Safety Profile of Vitamin B12: What the Evidence Shows

Vitamin B12 has one of the most favorable safety profiles of any micronutrient supplement. The Institute of Medicine has not established a Tolerable Upper Intake Level for B12 because no adverse effects have been identified from high oral or intramuscular doses in healthy adults. [10]

No Cardiovascular Signal from High-Dose B12

The NORVIT trial (N=3,749, published in New England Journal of Medicine) tested high-dose B-vitamin supplementation (including 0.4 mg B12 daily) after acute MI. The trial found no increase in cardiovascular events from B12 and no interaction with any co-administered cardiovascular medications. [11]

Acne and Rosacea: A Minor Caution

A 2015 case series and mechanistic study in Science Translational Medicine (N=10) found that very high-dose B12 supplementation may trigger acne flares in a subset of individuals by altering the porphyrin metabolism of Cutibacterium acnes on skin. [12] This is unlikely to be relevant to the modest doses used for deficiency correction but is worth mentioning to cosmetically motivated patients asking about megadose B12 injections.

Alirocumab Drug Interactions That Actually Exist

Because patients often ask whether combining supplements with Praluent is safe, it helps to clarify what interactions are actually documented for this drug.

Statins: Expected and Managed

High-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) are frequently co-prescribed with alirocumab. No adverse pharmacokinetic interaction exists. The LDL-C lowering effects are additive. ODYSSEY LONG TERM enrolled predominantly statin-background patients, and no safety signal emerged from statin co-administration. [2]

Ezetimibe: Additive Without Interaction

Ezetimibe inhibits NPC1L1, reducing intestinal cholesterol absorption. Adding alirocumab to ezetimibe produces additive LDL-C reduction. No metabolic interaction pathway exists between the two agents.

Coumarin Anticoagulants (Warfarin): Limited Data, Monitoring Recommended

The FDA label notes that patients on warfarin had INR changes during major illness (which can itself alter INR), but no causal interaction between alirocumab and warfarin has been established. Standard INR monitoring applies.

What Alirocumab Does NOT Interact With

Because alirocumab is not metabolized by CYP enzymes, it does not interact with:

• CYP3A4 substrates (certain statins, macrolides, azole antifungals)
• CYP2C19 substrates (clopidogrel, omeprazole)
• P-glycoprotein substrates
• Any water-soluble vitamin

Vitamin B12, being entirely outside these pathways, sits firmly in the no-interaction category.

Elevated Homocysteine: The Overlap Worth Knowing

One metabolic detail connects B12 status and cardiovascular risk without involving alirocumab directly. B12 deficiency raises plasma homocysteine by impairing methionine synthase. Elevated homocysteine has been associated with increased ASCVD risk, though Mendelian randomization studies have not confirmed it as a causal driver. [13]

Regardless of causality, patients with ASCVD being treated with alirocumab are exactly the population who benefit from addressing modifiable cardiovascular risk factors. B12 repletion in a deficient patient lowers homocysteine by approximately 7 micromol/L in most studies, which is a reasonable secondary goal in this group. [14]

When to Loop In Your Prescriber

Most patients taking Praluent can add a standard-dose B12 supplement without any conversation with their physician. The supplement is safe, the interaction risk is zero, and the potential benefit (especially in metformin users) is real.

Contact your prescriber or care team if you notice:

• New or worsening numbness, tingling, or burning in the feet or legs (could indicate undetected B12 deficiency neuropathy requiring evaluation rather than just supplementation)
• Fatigue and macrocytic anemia on routine labs (suggests deficiency severe enough to require workup for underlying cause)
• Any neurological symptoms that have appeared since starting metformin (B12 deficiency neuropathy is reversible early but not if left untreated for months)

Summary of Clinical Recommendations

Patients on alirocumab (Praluent) can take vitamin B12 without restriction. No interaction of any pharmacological type exists between these two agents. The relevant clinical question is not whether B12 is safe with Praluent, but whether B12 monitoring and supplementation are warranted given the patient's full medication list and diet.

Patients on metformin should have serum B12 checked at baseline and annually per ADA Standards of Care. [8] Those with levels below 300 pg/mL should start 1,000 mcg oral cyanocobalamin daily and recheck in 8-12 weeks. Patients on alirocumab who are not on metformin, are not vegan, and are younger than 65 do not need routine B12 supplementation unless a deficiency is found on standard labs.

The ADA Standards of Medical Care in Diabetes (2024) states directly: "Long-term metformin use is associated with biochemical vitamin B12 deficiency. Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially those with peripheral neuropathy or anemia." [8] This recommendation applies to the alirocumab patient taking metformin, not to alirocumab itself.

Check serum B12 at your next lab visit if you have been on metformin for more than one year.